ResMed Inc. vs Super Micro Computer Inc — how do they compare? ResMed Inc. trades at $230.05 (market cap $31.89B), while Super Micro Computer Inc trades at $41.86 (market cap $28.10B). The key difference: ResMed Inc. and Super Micro Computer Inc are close in size by market cap, and ResMed Inc. pays a 1.16% dividend while Super Micro Computer Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold ResMed Inc. for 51 Days and Super Micro Computer Inc for 19 Days on average.
| RMD | SMCI | |
|---|---|---|
Market Cap | $31.89B | $28.10B |
Volume | 618,314 | 38,581,805 |
Sector | Health | Technology |
52-Week High | $275.96 | $55.04 |
52-Week Low | $182.82 | $20.53 |
Typical Hold Time | 51 Days | 19 Days |
Enterprise Value | $31.24B | $33.56B |
Dividend Yield | 1.16% | — |
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $226.73, up 0.33% on the day, with a bullish technical signal supported by moving averages. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $5.15 billion in 2025, with a net income margin of 26.94%, while cash flow from operations reached $1.75 billion. Recent news highlights an upcoming earnings report and positive analyst commentary on growth prospects.
The outlook is positive, driven by consistent earnings outperformance and a consensus price target of $242.70, implying upside. Key risks include competitive pressures and ongoing legal investigations. Institutional interest remains strong, with recent stake increases by funds. The stock's valuation metrics, such as a P/E of 21.74, appear reasonable given growth expectations.
Super Micro Computer (SMCI) trades at $42.77, down 4.85% on the day, with a bullish technical signal and strong fundamental performance. Recent earnings beats and robust revenue growth to $39.1B in 2026 highlight its AI infrastructure strength. The stock is near its consensus price target of $42.33, with support at $42 and resistance at $44.
Outlook remains positive driven by AI server demand, though risks include margin pressure and a DOJ investigation. Analysts are mixed with 36% buy ratings, but the low P/E of 13.12 offers value if growth sustains. Investors should weigh execution risks against the company's strategic position in expanding AI markets.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →Super Micro Computer, Inc., commonly known as Supermicro, is a leading provider of high-performance and high-efficiency server technology and innovation. The company specializes in designing, manufacturing, and selling advanced server, storage, and networking solutions, primarily for data centers, cloud computing, artificial intelligence, and 5G/Edge computing markets. SMCI's modular architecture allows for the rapid delivery of customized and purpose-built solutions, making it a key player in the enterprise computing and specialized AI infrastructure space.
Read more on SMCI →